Table I.
CLEC3B expression | ||||
---|---|---|---|---|
Clinicopathological features | All cases | Mean | 95% confidence interval | P-value |
Sex | 0.0624 | |||
Female | 188 | 1,120 | 994.5–1,246 | |
Male | 345 | 1,080 | 943.2–1,218 | |
Age | 0.9971 | |||
≤60 | 265 | 1,056 | 942.3–1,169 | |
>60 | 268 | 1,133 | 970.3–1,296 | |
T | <0.0001 | |||
T1-T2 | 342 | 1,243 | 1,102–1,383 | |
T3-T4 | 191 | 829.5 | 723.5–935.4 | |
N | 0.0107 | |||
N0 | 239 | 1,014 | 843.3–1,184 | |
N1 | 16 | 492.6 | 235.5–749.8 | |
M | 0.0001 | |||
M0 | 442 | 1,154 | 1,039–1,268 | |
M1 | 81 | 722 | 571.8–872.2 | |
Stage | <0.0001 | |||
Stage I–II | 324 | 1,266 | 1,121–1,412 | |
Stage III–IV | 206 | 831.9 | 726.1–937.7 | |
Grade | <0.0001 | |||
G1-G2 | 242 | 1,302 | 1,138–1,466 | |
G3-G4 | 283 | 886.5 | 775.4–997.6 |
A Mann Whitney test was used for statistical analysis. T, size or direct extent of the primary tumor; N, degree of spread to reginal lymph nodes; M, presence of distant metastasis; CLEC3B, C-Type Lectin Domain Family 3 Member B.